TaiGen Biotech signs up deal for Taigexyn in Russia and other states

15 January 2014

Taiwan-based drug developer TaiGen Biotechnology has signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company with annual sales of $1.8 billion, to develop and commercialize nemonoxacin (trade name Taigexyn)in the Russian Federation, Turkey and other members of the Commonwealth Independent States (CIS).

Nemonoxacin is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the deal, R-Pharm will be responsible for the development, registration and commercialization of nemonoxacin in these territories and assume all associated costs.

In exchange for the exclusive rights, TaiGen will receive an undisclosed upfront payment and is eligible for additional regulatory and commercial milestones as well as royalties on product sales in the future. TaiGen acquired worldwide rights to nemonoxacin from Warner Chilcott (now a subsidiary of Actavis) in 2011 (The Pharma Letter December 11, 2011).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK